WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGen's SmartChip(TM) High-throughput Real-Time PCR System

WaferGen Announces that University of Texas Southwestern Medical Center
Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGen's
SmartChip(TM) High-throughput Real-Time PCR System

FREMONT, Calif., Nov. 12 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc.
(OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic
analysis systems, today announced that the University of Texas Southwestern
Medical Center demonstrated the utility of WaferGen's new proprietary
SmartChip(TM) Nano-dispenser. The Nano-dispenser is used for loading samples
and enzymes onto content-ready SmartChips for use with WaferGen's
SmartChip(TM) Real-Time PCR System. The SmartChip Real-Time PCR System is
designed to boost pathway-based gene discovery and exploration enabling
researchers to discover new gene markers that could be missed using current
microarray methods of discovery.

"The SmartChip Nano-dispenser enables the loading of a single sample into
5,184 nano-wells in a single step in approximately 20 minutes--at least three
times faster than standard nano-dispensers," said Spencer Brown, Ph.D.,
Director of Plastic Surgery Research, Nancy Lee and Perry Bass of the Advanced
Wound Healing Laboratory at UT Southwestern. "It is simple, easy to use,
reliable, and cost-effective since we don't need to purchase elaborate and
expensive equipment. Furthermore, its small footprint provides an added
advantage of requiring less space. This contributes to our ability to use the
SmartChip system to conduct gene expression research at a fraction of the time
and cost of existing instrument systems."

"By demonstrating the utility of the SmartChip Nano-dispenser, UT Southwestern
has provided additional verification of the role that the SmartChip system can
play in decreasing research time and increasing the cost-efficiency of
validating relevant gene expression biomarkers, and eventually assessing their
impact on patient response to treatment," said Alnoor Shivji, Chairman and
CEO, WaferGen. "This decrease in research time has broad economic
implications for researchers discovering biomarkers and across the drug
development industry, particularly for companies seeking ways to reduce time
to market for their therapeutics or diagnostic products."

In January 2009, WaferGen and UT Southwestern established a collaboration
under which UT Southwestern is conducting novel research projects using the
SmartChip Real-Time PCR System in order to identify and validate gene
expression biomarkers related to wound healing. Subsequent to this agreement,
in March 2009, WaferGen and UT Southwestern established a novel wound healing
research collaboration with IR BioSciences Holdings, Inc., a development-stage
biotechnology company focused on the research, development and licensing of
ImmuneRegen's wound healing drug candidate, Homspera®.

About the SmartChip Real-Time PCR System
The SmartChip Real-Time PCR System is designed as the first whole genome,
high-throughput gene expression real-time PCR platform. This innovative
system, combined with next-generation chemistry and optimized assays being
developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief
Scientific Officer and one of the pioneers of PCR, promises to deliver
significant speed and cost advantages to researchers in the gene expression
and genotyping markets. Based on collaborations established with leading
research institutions, WaferGen believes that the SmartChip Real-Time PCR
System is positioned as the platform of choice for biomarker discovery and
validation. The system will provide a number of key ease-of-use features
including content-ready chips with gene panels optimized for micro RNA,
cancer, and whole genome. WaferGen believes the SmartChip Real-Time PCR
System will be the first platform to combine the high-throughput capability
and cost efficiencies of existing microarrays, with the sensitivity and
accuracy of real-time PCR.

About WaferGen
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale
of state-of-the-art systems for genetic analysis for the life science and
pharmaceutical industries. The company is actively developing its
SmartChip(TM) product for the gene expression and genotyping markets.
WaferGen currently markets its SmartSlide(TM) family of products to companies
and organizations involved in stem cell and cell biology research. SmartSlide
represents the first fluidics integrated micro-incubators enabling cell
biology and stem cell research.

Forward-Looking Statements
This press release contains certain "forward-looking statements". Such
statements include statements relating to the expected benefits and advantages
of the SmartChip Nano-dispenser, the expected benefits and advantages of the
SmartChip technology to other applications, and other statements relating to
future events or to the company's future financial performance and are not
historical facts, including statements which may be preceded by the words
"intends," "may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential" or similar
words.

Forward-looking statements are not guarantees of future performance, are based
on certain assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of the company. Actual
results may differ materially from the expectations contained in the
forward-looking statements. Factors that may cause such differences include
the risks that: (i) the company may be unsuccessful in commercially developing
its products or in achieving market acceptance of new and relatively unproven
technologies; (ii) the company will need to raise additional capital to meet
its business requirements in the future and the company may not be able to do
so on reasonable terms or at all; (iii) the company's proprietary intellectual
property rights may not adequately protect its products and technologies; and
(iv) the company expects intense competition in its target markets, including
from companies that have much greater resources than the company, and there
can be no assurance that the company will be able to compete effectively.
More detailed information about the company and the risk factors that may
affect the realization of forward-looking statements is set forth in the
company's filings with the Securities and Exchange Commission, including the
company's Annual Report on Form 10-K for the year ended December 31, 2008 and
the company's Quarterly Report on Form 10-Q for the quarter ended June 30,
2009. Investors and security holders are urged to read this document free of
charge on the SEC's web site at www.sec.gov. The company does not undertake
to publicly update or revise its forward-looking statements as a result of new
information, future events or otherwise.

Contacts:
WaferGen
Mona Chadha
510-651-4450
Mona.chadha@wafergen.com

SOURCE WaferGen Biosystems, Inc.

Mona Chadha of WaferGen, +1-510-651-4450, Mona.chadha@wafergen.com